Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $285,150.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 5,000 shares of the firm’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the completion of the sale, the vice president now owns 33,492 shares of the company’s stock, valued at $1,910,048.76. This trade represents a 12.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Patrick Lamy also recently made the following trade(s):

• On Monday, December 16th, Patrick Lamy sold 1,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.13, for a total transaction of $29,130.00.
• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Stock Performance

Shares of NASDAQ:AKRO opened at $54.08 on Friday. The company’s 50 day simple moving average is $30.26 and its 200 day simple moving average is $28.88. The stock has a market capitalization of $3.77 billion, a price-to-earnings ratio of -14.42 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Morgan Stanley raised their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research report on Tuesday. UBS Group raised their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $35.00 to $63.00 in a research report on Thursday. Citigroup raised their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, HC Wainwright raised their target price on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Akero Therapeutics presently has an average rating of “Buy” and an average price target of $75.86.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AKRO. Wellington Management Group LLP increased its stake in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after acquiring an additional 2,782,029 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Akero Therapeutics during the third quarter worth $37,392,000. SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after purchasing an additional 583,486 shares during the period. RTW Investments LP lifted its holdings in shares of Akero Therapeutics by 9.0% during the third quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after purchasing an additional 487,450 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Akero Therapeutics by 2.9% during the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after purchasing an additional 201,225 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.